Verrica Pharmaceuticals (VRCA)

Verrica Pharmaceuticals (VRCA) Income Statement


Verrica Pharmaceuticals Income Statement

Last quarter (Q4 2022), Verrica Pharmaceuticals's total revenue was $68.00K, an increase of Infinity% from the same quarter last year. In Q4, Verrica Pharmaceuticals's net income was $-5.93M. See Verrica Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 9.03M$ 9.03M$ 12.00M$ 0.00$ 0.00$ 0.00
Cost of Revenue
$ 62.00K$ 725.00K----
Gross Profit
$ 6.00K$ 8.31M----
Operating Expense
$ 29.60M$ 29.60M$ 42.91M$ 40.18M$ 30.08M$ 21.88M
Operating Income
$ -21.29M$ -21.30M$ -30.91M$ -40.18M$ -30.08M$ -21.88M
Net Non Operating Interest Income Expense
$ -1.75M$ -1.70M$ -4.17M$ -2.51M$ 1.88M$ 1.23M
Other Income Expense
$ -1.44M$ -1.50M-$ -1.00K$ -4.00K$ -1.00K
Pretax Income
$ -24.49M$ -24.49M$ -35.08M$ -42.69M$ -28.21M$ -20.65M
Tax Provision
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -24.49M$ -24.49M$ -35.08M$ -42.69M$ -28.21M$ -20.65M
Basic EPS
$ -0.82$ -0.72$ -1.30$ -1.71$ -1.13$ -1.41
Diluted EPS
$ -0.82$ -0.72$ -1.30$ -1.71$ -1.13$ -1.41
Basic Average Shares
$ 136.51M$ 34.16M$ 27.04M$ 25.00M$ 24.90M$ 14.66M
Diluted Average Shares
$ 140.86M$ 34.16M$ 27.04M$ 25.00M$ 24.90M$ 14.66M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
-$ -0.51$ -1.02---
Reported Normalized Diluted E P S
-$ -0.51----
Rent Expense Supplemental
Total Expenses
$ 30.33M$ 30.33M$ 42.91M$ 40.18M$ 30.08M$ 21.88M
Net Income From Continuing And Discontinued Operation
$ -24.49M$ -24.49M$ -35.08M$ -42.69M$ -28.21M$ -20.65M
Normalized Income
$ -23.62M$ -23.05M$ -35.08M$ -42.69M$ -28.21M$ -20.65M
Interest Expense
$ 2.23M$ 2.17M$ 4.29M$ 3.03M$ 0.00$ 0.00
$ -22.26M$ -22.32M$ -30.79M$ -39.66M$ -28.21M$ -21.88M
$ -21.54M$ -21.60M$ -30.31M$ -39.43M$ -27.95M$ -21.86M
Currency in USD

Verrica Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis